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c o n c i s e c o m m u n i c a t i o n
table 1. Cancer-Specific Rates of CDI
Rate Cases Total patients Percentage
Allogeneic HSCTa 83 307 27
Autologous HSCT 27 290 9.0
Leukemia/MDS 53 426 12.4
Lymphoma 37 1,189 3.1
Solid tumors 317 22,889 1.4
note. Clostridium difficile infection (CDI) rates by un-
derlying cancer at Memorial Sloan Kettering Cancer Cen-
ter, 2008–2009. HSCT, hematopoietic stem cell transplant;
MDS, myelodysplastic syndrome.
a Includes adult and pediatric cases.
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A multicenter survey of 11 cancer centers was performed to deter-
mine the rate of hospital-onset Clostridium difficile infection (HO-
CDI) and surveillance practices. Pooled rates of HO-CDI in patients
with cancer were twice the rates reported for all US patients (15.8
vs 7.4 per 10,000 patient-days). Rates were elevated regardless of
diagnostic test used.
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In 2011, an estimated 1.6 million people underwent treatment
for cancer.1 Clostridium difficile is the most common bacterial
cause of healthcare-associated diarrhea in persons receiving
chemotherapy for cancer. Several risk factors in this popu-
lation raise the risk of C. difficile infection (CDI).2,3 In the
last decade, with the emergence of BI/NAP1 strain the in-
cidence and severity of CDI increased across North America
and Europe, and the need for widespread surveillance became
more important than ever.4
At Memorial Sloan Kettering Cancer Center (MSKCC),
CDI rates are highest among hematopoietic stem cell trans-
plant (HSCT) recipients and those undergoing chemotherapy
for leukemia (unpublished data; Table 1). Studies from other
cancer centers have also reported a higher rate of CDI com-
pared to the general population, with strikingly high rates
among allogeneic HSCT recipients.5
With the advent of public reporting for CDI, comparison
of rates across centers will occur and may not take into ac-
count differences in patient populations. Therefore, we
sought to determine the rate of hospital-onset (HO)-CDI and
surveillance practices in a population of HSCT recipients and
patients with cancer. Establishment of a benchmark for this
large but unique patient group will assist both infection con-
trol practitioners and concerned consumers as they compare
rates across states and hospitals.
methods
In sum, 10 of 11 participants were members of the Com-
prehensive Cancer Center’s Infection Control Group (C3IC
network). The participating centers included MSKCC, Fox
Chase Cancer Center, Roswell Park Cancer Institute, Moffitt
Cancer Center, MD Anderson Cancer Center, Barnes-Jewish
Hospital, James Cancer Hospital at Ohio State University
Medical Center, Dana-Farber Cancer Institute, Barbara Ann
Karmanos Cancer Institute, Thornton Hospital, University of
California–San Diego, and New York University Langone
Medical Center. Data were collected electronically using a
secure website and were considered exempt from institutional
review board.
Participating centers provided specific information in re-
sponse to the C. difficile surveillance questionnaire. Infor-
mation submitted included (1) oncology-specific hospital
characteristics, including number of oncology and bone mar-
row transplant (BMT) beds; (2) laboratory method of C.
difficile detection—enzyme immunoassay (EIA), cytotoxin as-
say (CTA), or polymerase chain reaction (PCR); (3) surveil-
lance definition for (a) HO-CDI and (b) definition of relapse
versus second new infection; (4) most recent rates of HO-
CDI (annual rate for 2010 or YTD rate for 2011). Rates were
calculated as the number of HO-CDI cases per oncology-
specific patient-days. Additional queries included informa-
tion on duration of isolation practice for C. difficile cases.
results
A total of 11 centers participated in the survey. Hospital
characteristics are shown in Table 2. Among the centers, the
number of oncology beds ranged from 22 to 600 (median,
100 beds); HSCT beds, 6–80 (median, 26 beds). PCR was the
most common detection method (6), followed by EIA (4)
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table 2. Hospital Characteristics of Participating Centers
Hospital
Characteristic A B C D E F G H I J K
No. of beds
Oncology 435 109 100 24 600 27 185 125 56 26 22
Transplant 22 14 0 30 68 18 24 32 28 80 6
Diagnostic test PCR EIA CTA PCR EIA PCR CTA/PCRa EIA PCR EIA PCR
Surveillance definition
HO-CDI (positive
test from time of ad-
mission), hours 148 148 148 172 148 172 172 172 148 172 172
Second new infection
(time from index






symptoms Yes (2 days) Yes Yes Yes Yes Yes Yes Yes Yes
Minimum treatment
duration 7 Complete
Entire hospitalization Yes Yes
note. CTA, cytotoxin assay; EIA, enzyme immunoassay; HO-CDI, hospital-onset Clostridium difficile infection; NA, not available;
PCR, polymerase chain reaction.
a Center with recent transition from CTA to PCR; rates were reported while CTA was in use.
and CTA (1). Six centers are located in states where C. difficile
is a reportable healthcare-associated infection (HAI).
Rates of HO-CDI. A case of HO-CDI was defined as a
positive result of a laboratory assay for C. difficile toxin A
and/or B following in-patient admission. The cutoff used was
148 hours at 5 centers and 172 hours at 6 centers.
Centers using PCR as detection method had a higher me-
dian HO-CDI rate (1.72 per 1,000 patient-days) compared
to EIA (0.9 per 1,000 patient-days; Figure 1). Among the
centers that use PCR, the median HO-CDI rate was highest
when the 48-hour cutoff from admission was used to define
an HO-CDI case: 2.2 per 1,000 patient-days (more than 48
hours) and 1.57 per 1,000 patient-days (more than 72 hours).
Relapse versus second new infection. Most centers followed
the ad hoc C. difficile surveillance working group’s criteria
for recurrent infection.6 In total, 7 of 9 centers that track
recurrent cases consider an episode occurring more than 8
weeks after the index episode as a second new infection. One
center uses 12 weeks as the interval and another center only
considers a recurrent episode occurring at least 6 months
after the index episode as second new infection.
Duration of isolation. Isolation practice for C. difficile varied
widely across all centers. Two of 11 centers isolated patients
with CDI for the entire duration of hospitalization. The re-
maining centers isolated patients until resolution of symp-
toms. Duration of treatment was used as criterion in addition
to symptom resolution at 2 centers, each requiring at least 7
days of treatment and complete therapy in addition to res-
olution of diarrhea.
discussion
We found the rate of HO-CDI in a large group of cancer
patients to be well above the reported rate for all US patients
(New York 2010, 0.82; California 2010–2011, 0.70; Ohio 2006,
0.7–0.8 per 1,000 patient-days).7–9 The rate was elevated re-
gardless of diagnostic test used. More recently, NHSN re-
ported pooled hospital rate of HO-CDI of 7.4 per 10,000
patient-days. In this report 33% of centers used nucleic acid
amplification test as the diagnostic assay. The pooled rate of
HO-CDI in our study is more than twice the NHSN rate
(15.8 per 10,000 patient-days), despite a comparable break-
down of diagnostic assays used.10
Persons with cancer are at high risk of CDI. In addition,
other factors make surveillance particularly challenging in this
population. First, most cancer centers have transitioned to
molecular-based testing for C. difficile in contrast to low-
sensitivity detection methods such as EIA.11 The proposed
surveillance definitions do not take into account the higher
sensitivity of the newer tests, which has been reported to
increase rates of HO-CDI by 2-fold in some studies.6,12,13 Sec-
ond, surveillance definitions are not universally applicable
because of the frequent healthcare-related exposure during
treatment for cancer, as well as likely higher frequency of
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figure 1. Hospital-onset Clostridium difficile infection rates (per
1,000 patient-days) among participating centers stratified by diag-
nostic test used. EIA, enzyme immunoassay; HA-CDAD, hospital-
acquired C. difficile–associated diarrhea; PCR, polymerase chain re-
action.
testing. Finally, rates of CDI among cancer patients are likely
to rise with better survival and the growing use of intensive
chemotherapeutic regimens and HSCT, especially among
older adults, a group at heightened risk for CDI.
Although previous reports in immunocompromised hosts
have shown elevation of CDI rates, this study is novel in its
examination of the rate across a large number of hospitals
and patients. There are several possible explanations for this
finding: CDI is a well-recognized complication of antineo-
plastic chemotherapy; healthcare exposure and antibiotic use
(especially fluoroquinolones) may be greater in the popula-
tion and for patients with HSCT; length of stay is substantially
longer.
Another substantial contributor is selection of diagnostic
test. EIAs for the detection of C. difficile toxins are the most
widely used tests for diagnosis of CDI. The poor sensitivity
of these tests is particularly problematic for control efforts.
As a result, molecular-based testing methods for CDI are now
approved by the Food and Drug Administration and increas-
ingly being implemented at many places. For institutions
making such a transition in states where CDI reporting is
mandatory, such as Cleveland Clinic (Ohio) and MSKCC
(New York), the rates of HO-CDI have doubled in the absence
of epidemiologic evidence of transmission, including lack of
clustering and homology by molecular typing of the isolated
strains.12,13 In our study, the majority of participants used
PCR for diagnosis. Despite the small numbers, the impact of
diagnostic test on HO-CDI rates is apparent (Figure 1).
Our study has several limitations, including small number
of participating centers from widespread geographic areas. To
improve compliance our survey included information for
rates only, patient-days that were not reported, and testing
for statistical significance not possible.
We report several important findings. First, we found a
high incidence of HO-CDI among patients undergoing treat-
ment for cancer. Second, we demonstrate the impact of di-
agnostic tests on HO-CDI rates, suggesting the urgent need
for standardization of methodology prior to interhospital
comparison or widespread public access to HAI-related in-
formation. Finally, we demonstrate the strength of specialized
infection control groups such as the C3IC network in com-
bining data to develop HAI benchmarks for specialized
populations.
As the Centers for Disease Control and Prevention and
designated organizations devise surveillance strategies, it is
crucial to recognize the multitude of factors that affect the
occurrence of HAI in persons undergoing treatment for can-
cer and its impact in the context of public reporting and the
looming risk of financial penalties. Targets for CDI should
be based on rates derived from homogenous populations that
employ similar surveillance and diagnostic strategies.
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